Immune Health Supplements Market (By Product: Vitamin and Mineral Supplements, Herbal Supplements, Probiotic Supplements; By Form: Capsules, Tablets, Powder, Liquid, Gel, Soft gels, Others; By Application: Hair growth, Others; By Mode Of Medication: Prescription based, Self-medication; By Distribution Channel: Pharmacies/Drug Stores, Supermarkets and Hypermarkets, E-commerce, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Immune Health Supplements Market, By Product

7.1.  Immune Health Supplements Market, by Product, 2021-2030

7.1.1.    Vitamin and Mineral Supplements

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Herbal Supplements

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Probiotic Supplements

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Others

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Immune Health Supplements Market, By Form

8.1.  Immune Health Supplements Market, by Form, 2021-2030

8.1.1.    Capsules

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Tablets

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Powder

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Liquid

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Gel

8.1.5.1.        Market Revenue and Forecast (2017-2030)

8.1.6.    Soft gels

8.1.6.1.        Market Revenue and Forecast (2017-2030)

8.1.7.    Others

8.1.7.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Immune Health Supplements Market, By Application

9.1.  Immune Health Supplements Market, by Application, 2021-2030

9.1.1.    Hair growth

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Gut health

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Respiratory tract infection

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Others

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Immune Health Supplements Market, By Mode Of Medication

10.1.        Immune Health Supplements Market, by Mode Of Medication, 2021-2030

10.1.1.  Prescription based

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Self-medication

10.1.2.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Immune Health Supplements Market, By Distribution Channel

11.1.        Immune Health Supplements Market, by Distribution Channel, 2021-2030

11.1.1.  Pharmacies/Drug Stores

11.1.1.1.      Market Revenue and Forecast (2017-2030)

11.1.2.  Supermarkets and Hypermarkets

11.1.2.1.      Market Revenue and Forecast (2017-2030)

11.1.3.  E-commerce

11.1.3.1.      Market Revenue and Forecast (2017-2030)

11.1.4.  Others

11.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 12.      Global Immune Health Supplements  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, by Product (2017-2030)

12.1.2.  Market Revenue and Forecast, by Form (2017-2030)

12.1.3.  Market Revenue and Forecast, by Application (2017-2030)

12.1.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.1.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.1.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.1.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.1.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.1.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.7.  Rest of North America

12.1.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.1.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.1.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.1.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.1.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, by Product (2017-2030)

12.2.2.  Market Revenue and Forecast, by Form (2017-2030)

12.2.3.  Market Revenue and Forecast, by Application (2017-2030)

12.2.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7.  Germany

12.2.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8.  France

12.2.8.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.8.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.8.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.8.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.8.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.9.  Rest of Europe

12.2.9.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.9.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.9.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.9.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.9.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, by Product (2017-2030)

12.3.2.  Market Revenue and Forecast, by Form (2017-2030)

12.3.3.  Market Revenue and Forecast, by Application (2017-2030)

12.3.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7.  China

12.3.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8.  Japan

12.3.8.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.8.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.8.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.8.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.8.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.9.  Rest of APAC

12.3.9.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.9.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.9.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.9.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.9.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, by Product (2017-2030)

12.4.2.  Market Revenue and Forecast, by Form (2017-2030)

12.4.3.  Market Revenue and Forecast, by Application (2017-2030)

12.4.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7.  North Africa

12.4.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8.  South Africa

12.4.8.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.8.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.8.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.8.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.8.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.9.  Rest of MEA

12.4.9.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.9.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.9.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.9.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.9.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, by Product (2017-2030)

12.5.2.  Market Revenue and Forecast, by Form (2017-2030)

12.5.3.  Market Revenue and Forecast, by Application (2017-2030)

12.5.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.5.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.5.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.5.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.5.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.5.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.7.  Rest of LATAM

12.5.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.5.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.5.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.5.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.5.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13.  Company Profiles

13.1.              Bayer AG

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Pfizer Inc.

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Sun Pharmaceutical Industries Limited

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Swisse Wellness Pty Ltd.

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              GlaxoSmithKline Inc.

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Abbott Laboratories

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              Amway Corp.

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              The Nature's Bounty Co.

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              Herbalife Nutrition of America, Inc.

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Himalaya Global Holdings Ltd.

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

13.11.           American Health

13.11.1.               Company Overview

13.11.2.               Product Offerings

13.11.3.               Financial Performance

13.11.4.               Recent Initiatives

13.12.           Unilever

13.12.1.               Company Overview

13.12.2.               Product Offerings

13.12.3.               Financial Performance

13.12.4.               Recent Initiatives

13.13.           Sanofi

13.13.1.               Company Overview

13.13.2.               Product Offerings

13.13.3.               Financial Performance

13.13.4.               Recent Initiatives

13.14.           Novartis

13.14.1.               Company Overview

13.14.2.               Product Offerings

13.14.3.               Financial Performance

13.14.4.               Recent Initiatives

13.15.           Boehringer Ingelheim

13.15.1.               Company Overview

13.15.2.               Product Offerings

13.15.3.               Financial Performance

13.15.4.               Recent Initiatives

13.16.           Nestlè

13.16.1.               Company Overview

13.16.2.               Product Offerings

13.16.3.               Financial Performance

13.16.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

15.2.              Glossary of Terms

Report Details

  • Report Code:38603
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:October 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers